EFFICACY AND SAFETY OF NON-HORMONAL NK- 3 RECEPTOR ANTAGONISTS FOR VASOMOTOR SYMPTOMS OF MENOPAUSE: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6780Keywords:
Menopause, Vasomotor Symptoms, Hot Flashes, Neurokinin 3 Receptor Antagonists, Fezolinetant, Elinzanetant, Non-Hormonal Therapy, Quality Of Life, Sleep Quality, Hepatic SafetyAbstract
Background: Vasomotor symptoms (VMS) affect up to 80% of menopausal women. Estrogen withdrawal-induced hyperactivity of hypothalamic KNDy neurons makes NK3 receptor antagonism a targeted non-hormonal therapeutic strategy.
Aim: To evaluate the efficacy, impact on sleep and quality of life, and safety (specifically liver function) of NK3 receptor antagonists for moderate-to-severe menopausal VMS.
Materials and methods: A PRISMA-guided systematic search across PubMed and Scopus (July 15, 2026) yielded 412 records, screened independently by five reviewers via Rayyan. Randomized controlled trials and cohort studies evaluating NK3 antagonists (fezolinetant, elinzanetant, pavinetant, GS1-144) versus placebo in peri-/postmenopausal women were included. Key outcomes were VMS frequency/severity, sleep (PROMIS SD), quality of life (MENQOL), and adverse events.
Results: NK3 antagonists significantly and rapidly reduced VMS frequency and severity versus placebo, with sustained efficacy up to 52 weeks. Subjective sleep quality and MENQOL scores consistently improved, including in breast cancer patients on endocrine therapy. Side effects were predominantly mild (gastrointestinal, neurological) with no endometrial risks. Asymptomatic, transient transaminase elevations (>3×ULN) occurred as the primary adverse event, resolving upon discontinuation.
Conclusion: NK3 receptor antagonists are a highly effective, non-hormonal treatment for moderate-to-severe VMS that substantially improve sleep and quality of life. Periodic liver function monitoring is recommended due to potential transient transaminase elevations.
References
Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. https://doi.org/10.1001/jamainternmed.2014.8063 PMID: 25686030; PMCID: PMC4433164.
New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023 Jun 1;30(6):573-590. https://doi.org/10.1097/GME.0000000000002200 PMID: 37252752..
Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1-15. https://doi.org/10.1210/clinem/dgaa764 PMID: 33095879.
Davis SR, Baber RJ. Treating menopause - MHT and beyond. Nat Rev Endocrinol. 2022 Aug;18(8):490-502. https://doi.org/10.1038/s41574-022-00685-4 Epub 2022 May 27. PMID: 35624141.
Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013 Aug;34(3):211-27. https://doi.org/10.1016/j.yfrne.2013.07.003 Epub 2013 Jul 17. PMID: 23872331; PMCID: PMC3833827.
Padilla SL, Johnson CW, Barker FD, Patterson MA, Palmiter RD. A Neural Circuit Underlying the Generation of Hot Flushes. Cell Rep. 2018 Jul 10;24(2):271-277. https://doi.org/10.1016/j.celrep.2018.06.037 PMID: 29996088; PMCID: PMC6094949.
Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Nash Z, Doyle C, Papadopoulou DA, Bloom SR, Mohideen P, Panay N, Hunter MS, Veldhuis JD, Webber LC, Huson L, Dhillo WS. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 6;389(10081):1809-1820. https://doi.org/10.1016/S0140-6736(17)30823-1 Epub 2017 Apr 3. PMID: 28385352; PMCID: PMC5439024..
Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102. https://doi.org/10.1016/S0140-6736(23)00085-5 Epub 2023 Mar 13. PMID: 36924778.
Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, Kerr M, Panay N, Seitz C, Seymore S, Trower M, Zuurman L, Pawsey S. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023 Mar 1;30(3):239-246. https://doi.org/10.1097/GME.0000000000002138Epub 2023 Jan 30. PMID: 36720081; PMCID: PMC9970022.
Johnson, K. A., Martin, N., Nappi, R. E., Neal-Perry, G., Shapiro, M., Stute, P., Thurston, R. C., Wolfman, W., English, M., Franklin, C., Lee, M., Santoro, N. (1997). Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1981-. https://doi.org/10.1210/clinem/dgad058
Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstet Gynecol. 2023 Apr 1;141(4):737-747. https://doi.org/10.1097/AOG.0000000000005114 Epub 2023 Mar 9. PMID: 36897180; PMCID: PMC10026946.
Schaudig K, Wang X, Bouchard C, Hirschberg AL, Cano A, Shapiro C M M, Stute P, Wu X, Miyazaki K, Scrine L, Nappi RE. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024 Nov 18;387:e079525. https://doi.org/10.1136/bmj-2024-079525. Erratum in: BMJ. 2024 Nov 27;387:q2623. https://doi.org/10.1136/bmj.q2623 PMID: 39557487; PMCID: PMC11571049.
Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020 Apr;27(4):382-392. https://doi.org/10.1097/GME.0000000000001510 PMID: 32102086; PMCID: PMC7147405.
Kagan R, Cano A, Nappi RE, English ML, Mancuso S, Wu X, Ottery FD. Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. Adv Ther. 2025 Feb;42(2):1147-1164. https://doi.org/10.1007/s12325-024-03073-8 Epub 2024 Dec 30. PMID: 39739195; PMCID: PMC11787274.
Panay N, Joffe H, Maki PM, Nappi RE, Pinkerton JV, Simon JA, Soares CN, Thurston RC, Francuski M, Caetano C, Genga K, Haberland C, Haseli Mashhadi N, Laapas K, Parke S, Seitz C, Schwarz J, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA Intern Med. 2025 Nov 1;185(11):1319-1327. https://doi.org/10.1001/jamainternmed.2025.4421 PMID: 40920404; PMCID: PMC12418220.
Santoro N, Neal-Perry G, Stute P, Blogg M, Mancuso S, Morga A, Ottery FD, Siddiqui E. Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy. Curr Med Res Opin. 2025 Feb;41(2):375-384. https://doi.org/10.1080/03007995.2025.2470752 Epub 2025 Mar 5. PMID: 40044127.
Wang Y, Wang X, Wang W, Lin J, He Y, Chen H, Shou H, Ai X, Zhang Q, Cai Y, Wu Y, Guo R, Hu L, Chen H, Xiang W, Pan C, Yu Q. Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial. Menopause. 2026 Apr 14. https://doi.org/10.1097/GME.0000000000002748 Epub ahead of print. PMID: 41979542.
Stute P, Shapiro C M M, Morga A, Tai TA, Ajmera M, Muresan B, Martins K, Hua Y, Zhao A, Liu J, Nappi RE. Fezolinetant compared with elinzanetant for the treatment of vasomotor symptoms associated with menopause: A matching-adjusted indirect comparison. Maturitas. 2026 Feb;205:108782. https://doi.org/10.1016/j.maturitas.2025.108782 Epub 2025 Nov 24. PMID: 41418588.
Shapiro C M M, Neal-Perry G, Stute P, Thurston RC, Wolfman W, English M, Wu X, Ottery FD. Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysis. Maturitas. 2025 Dec;203:108740. https://doi.org/10.1016/j.maturitas.2025.108740 Epub 2025 Oct 6. PMID: 41259888.
Yu Q, Ming F, Ma J, Cai Y, Wang L, Ren M, Zhang J, Ma X, Miyazaki K, He W, Wang X. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial. J Int Med Res. 2024 May;52(5):3000605241246624. https://doi.org/10.1177/03000605241246624 PMID: 38818887; PMCID: PMC11143821.
Takamatsu K, Miki T, Miyazaki K, Hashimoto A, He W, Wang X. Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan. Climacteric. 2024 Aug;27(4):389-397. https://doi.org/10.1080/13697137.2024.2356854 Epub 2024 Jun 12. PMID: 38864290.
Shapiro C M M, Wu X, Wang X, Miyazaki K, Morga A, Nappi RE, Stute P, Martins K, Schaudig K. Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy. Maturitas. 2025 Feb;193:108159. https://doi.org/10.1016/j.maturitas.2024.108159 Epub 2024 Nov 26. PMID: 39809112.
Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, Hoveyda HR, Fraser GL. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. J Clin Endocrinol Metab. 2019 Dec 1;104(12):5893-5905. https://doi.org/10.1210/jc.2019-00677 PMID: 31415087.
Hsu CD, Carpenter RM, Richardson G, Guo F, Adekanmbi V, Hoang TN, Berenson AB. Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting. Menopause. 2026 May 1;33(5):529-535. https://doi.org/10.1097/GME.0000000000002703 PMID: 41493963; PMCID: PMC12948302.
Ruan X, Bai W, Ren M, Kim T, Lee JY, Chuang FC, Wang PH, He W, Ma X, Miyazaki K, Song N, Wang X, Yu Q. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I). J Int Med Res. 2024 May;52(5):3000605241247684. https://doi.org/10.1177/03000605241247684 PMID: 38818888; PMCID: PMC11143828.
Trigg A, Barclay M, Whyman S, Lehane A, Bradley H, Gerlinger C, Seitz C, Gater A, Haberland C. Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause. J Patient Rep Outcomes. 2025 May 7;9(1):50. https://doi.org/10.1186/s41687-025-00875-4 PMID: 40332718; PMCID: PMC12058613.
Haberland C, Barclay M, Whyman S, Lehane A, Gater A, Gerlinger C, Seitz C, Francuski M, Schoof N, Trigg A, Bradley H. Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes. J Patient Rep Outcomes. 2025 Jul 1;9(1):79. https://doi.org/10.1186/s41687-025-00914-0 PMID: 40591096; PMCID: PMC12214113.
Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Apr 1;31(4):247-257. https://doi.org/10.1097/GME.0000000000002340 PMID: 38517210; PMCID: PMC11896090.
Shapiro C M M, Cano A, Nappi RE, Santoro N, English ML, Mancuso S, Morga A, Siddiqui E, Valluri U, Ottery FD. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 2024 Aug;186:107999. https://doi.org/10.1016/j.maturitas.2024.107999 Epub 2024 May 15. PMID: 38749864.
Prague JK, Abbara A, Comninos AN, Jayasena CN, Higham CE, Adaway J, Keevil BG, Veldhuis JD, Dhillo WS. Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women. J Endocr Soc. 2019 Nov 14;4(2):bvz009. https://doi.org/10.1210/jendso/bvz009 PMID: 32318647; PMCID: PMC7159071.
Sassarini J, Skorupskaite K, McLean J, Lumsden MA, Anderson RA. NK3 receptor antagonist alters the centrally controlled perception of menopausal flushing - a pilot study. Climacteric. 2025 Aug;28(4):438-445. https://doi.org/10.1080/13697137.2025.2470462 Epub 2025 Mar 14. PMID: 40085748.
Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. N Engl J Med. 2025 Aug 21;393(8):753-763. https://doi.org/10.1056/NEJMoa2415566 Epub 2025 Jun 2. PMID: 40454634.
Christ JP, Navarro VM, Reed SD. Nonhormonal Therapies for Menopausal Vasomotor Symptoms. JAMA. 2023 Oct 3;330(13):1278-1279. https://doi.org/10.1001/jama.2023.15965 PMID: 37713186.
Nappi RE, Johnson KA, Stute P, Blogg M, English M, Morga A, Scrine L, Siddiqui E, Ottery FD. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). Menopause. 2024 Jun 1;31(6):512-521. https://doi.org/10.1097/GME.0000000000002354 Epub 2024 Apr 16. PMID: 38626380.
Pawsey, S., Simon, J. A., Anderson, R. A., Dhillo, W., Joffe, H., Trower, M. (1997). To the Editor. Menopause. 2020 Sep;27(9):1996-. https://doi.org/10.1097/GME.0000000000001619
Pawsey S, Mills EG, Ballantyne E, Donaldson K, Kerr M, Trower M, Dhillo WS. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234. https://doi.org/10.1210/clinem/dgab108 PMID: 33624806; PMCID: PMC8277204.
LaCroix A, Ensrud K. The flash dance of midlife: the Skylight 1 trial. Nat Med. 2023 Jun;29(6):1324-1325. https://doi.org/10.1038/s41591-023-02359-8 PMID: 37221383.
Sassarini J, Anderson RA. Elinzanetant: a phase III therapy for postmenopausal patients with vasomotor symptoms. Expert Opin Investig Drugs. 2024 Jan;33(1):19-26. https://doi.org/10.1080/13543784.2024.2305122 Epub 2024 Feb 12. PMID: 38224099.
Francke K, Klein S, Burke J, Schultze-Mosgau MH, Kay G. The Effects of Elinzanetant on Simulated Driving Performance in Healthy Women: A Randomized Phase I Study. Clin Transl Sci. 2025 Jul;18(7):e70282. https://doi.org/10.1111/cts.70282 PMID: 40569207; PMCID: PMC12199571.
Li Y, Liu Y, Iwai M, Takeuchi M, Song N, Li Y, Shi A. An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects. Drug Des Devel Ther. 2025 Mar 26;19:2243-2252. https://doi.org/10.2147/DDDT.S486562 PMID: 40160966; PMCID: PMC11955179.
Schultz NM, Morga A, Siddiqui E, Rhoten SE. Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause. Adv Ther. 2024 Jun;41(6):2233-2252. https://doi.org/10.1007/s12325-024-02787-z Epub 2024 Feb 24. Erratum in: Adv Ther. 2024 Jun;41(6):2543. https://doi.org/10.1007/s12325-024-02847-4. PMID: 38396203; PMCID: PMC11133125.
Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Nash Z, Doyle C, Papadopoulou DA, Bloom SR, Mohideen P, Panay N, Hunter MS, Veldhuis JD, Webber LC, Huson L, Dhillo WS. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 6;389(10081):1809-1820. https://doi.org/10.1016/S0140-6736(17)30823-1 Epub 2017 Apr 3. PMID: 28385352; PMCID: PMC5439024.
Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Mohideen P, Lin VH, Stern TP, Panay N, Hunter MS, Webber LC, Dhillo WS. Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. Menopause. 2018 Aug;25(8):862-869. https://doi.org/10.1097/GME.0000000000001090 PMID: 29533369; PMCID: PMC6092106.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Kalina Światlak , Justyna Trzaskalik, Wiktoria Żelazna , Jakub Sokołowski, Monika Leśniak

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

